Edgewise Therapeutics, Inc.
EWTX
$34.12
-$0.72-2.07%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.48% | -25.40% | -26.51% | -30.05% | -38.01% |
| Total Depreciation and Amortization | -0.73% | -1.05% | 5.74% | 12.59% | 15.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.28% | 122.63% | 137.99% | 150.57% | 119.72% |
| Change in Net Operating Assets | -130.90% | -152.03% | -134.21% | 29.45% | 517.85% |
| Cash from Operations | -25.53% | -31.91% | -21.38% | -20.46% | -21.06% |
| Capital Expenditure | 55.43% | 80.49% | 61.88% | 21.83% | 36.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.37% | 82.26% | 65.52% | 60.37% | 160.44% |
| Cash from Investing | -158.22% | 82.24% | 65.49% | 60.13% | 159.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,824.69% | -21.41% | -34.90% | -33.48% | -96.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 112.67% | 100.00% | 100.00% | -0.47% | -81.82% |
| Cash from Financing | 1,880.56% | -21.33% | -34.86% | -33.51% | -96.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.01% | 143.85% | -89.90% | -100.69% | 209.41% |